03.02.2010 • News

Millipore Q4 Beats Wall Street View

Millipore, a maker of purification systems used in drug manufacture, posted a better-than-expected
quarterly profit, helped by higher revenue from its bioprocess division.

Net income for the fourth quarter was about $44 million, or 78 cents a share, compared with $31.1 million, or 56 cents a share, in the year-ago quarter. Excluding items, the company posted earnings of $1 per share,
Millipore said in a statement. Revenue for the quarter rose 7% to $426 million.

Analysts on average expected the company to earn 94 cents a share, excluding items, on revenue of $421.5 million, according to Thomson Reuters I/B/E/S. Bioprocess division sales rose 9%, helped by strong
demand from the company's biotechnology customers and higher levels of vaccine production, Chief Executive Martin Madaus said.

Company

Millipore Corporation

17 Cherry Hill Drive
01923 Danvers

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.